Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BROLUCIZUMAB-DBLL Cause Visual acuity reduced? 365 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 365 reports of Visual acuity reduced have been filed in association with BROLUCIZUMAB-DBLL. This represents 13.0% of all adverse event reports for BROLUCIZUMAB-DBLL.

365
Reports of Visual acuity reduced with BROLUCIZUMAB-DBLL
13.0%
of all BROLUCIZUMAB-DBLL reports
1
Deaths
19
Hospitalizations

How Dangerous Is Visual acuity reduced From BROLUCIZUMAB-DBLL?

Of the 365 reports, 1 (0.3%) resulted in death, 19 (5.2%) required hospitalization, and 2 (0.5%) were considered life-threatening.

Is Visual acuity reduced Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BROLUCIZUMAB-DBLL. However, 365 reports have been filed with the FAERS database.

What Other Side Effects Does BROLUCIZUMAB-DBLL Cause?

Vitreous floaters (479) Visual impairment (446) Vision blurred (416) Eye inflammation (387) Retinal vasculitis (323) Uveitis (305) Vitritis (284) Eye pain (234) Vitreous opacities (205) Anterior chamber cell (199)

What Other Drugs Cause Visual acuity reduced?

RANIBIZUMAB (1,342) INSULIN LISPRO (1,172) AFLIBERCEPT (993) BELANTAMAB MAFODOTIN (708) BEVACIZUMAB (451) DIMETHYL (440) INSULIN GLARGINE (438) INTERFERON BETA-1A (396) INSULIN HUMAN (393) DEXAMETHASONE (340)

Which BROLUCIZUMAB-DBLL Alternatives Have Lower Visual acuity reduced Risk?

BROLUCIZUMAB-DBLL vs BROMAZEPAM BROLUCIZUMAB-DBLL vs BROMFENAC BROLUCIZUMAB-DBLL vs BROMHEXINE BROLUCIZUMAB-DBLL vs BROMOCRIPTINE BROLUCIZUMAB-DBLL vs BROTIZOLAM

Related Pages

BROLUCIZUMAB-DBLL Full Profile All Visual acuity reduced Reports All Drugs Causing Visual acuity reduced BROLUCIZUMAB-DBLL Demographics